| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/24/2009 | US7494653 Inoculating a patient with an effective amount of PcrV antigen; monoclonal antibodies specific for the PcrV antigen |
| 02/24/2009 | US7494646 Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| 02/24/2009 | US7494644 contacting a myocardial cells with genetic engineered mammalian cells modified to express a connexin 43 proteins, to establishing electrical coupling between cardiomyocytes and recombinant cells; treatment of cardiac disease or tissue repair |
| 02/24/2009 | CA2415364C Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors |
| 02/24/2009 | CA2360437C Method of acquiring immunological tolerance |
| 02/24/2009 | CA2329129C Stable gene formulations comprising saccharides |
| 02/24/2009 | CA2179029C Vertebrate embryonic pattern-inducing hedgehog-like proteins |
| 02/24/2009 | CA2174556C Recombinant p53 adenovirus methods and compositions |
| 02/19/2009 | WO2009023814A2 Hucbc treatment of amyloid associated disease |
| 02/19/2009 | WO2009023795A2 Cell-based compositions and method for treating conditions of the nervous system |
| 02/19/2009 | WO2009023525A2 Methods of modulating mesenchymal stem cell differentiation |
| 02/19/2009 | WO2009023333A2 Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines |
| 02/19/2009 | WO2009023055A2 Blockade of the inhibitory qa-1-cd94/nkg2a pathway for treatment of autoimmune disease |
| 02/19/2009 | WO2009023053A2 Use of rsk inhibitors to impede intracellular pathogen infections |
| 02/19/2009 | WO2009022174A2 Non-aggregating virus formulation |
| 02/19/2009 | WO2009021325A1 Microrna compositions and methods for the treatment of myelogenous leukemia |
| 02/19/2009 | WO2009002832A3 Inhibitors of ncca-atp channels for therapy |
| 02/19/2009 | WO2009002380A3 Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies |
| 02/19/2009 | WO2008157324A3 Peptide linked cell matrix materials for stem cells and methods of using the same |
| 02/19/2009 | WO2008156629A3 Methods and agents for inhibiting tumor growth by targeting the ssdna replication intermediate of tumor stem cells |
| 02/19/2009 | WO2008144365A3 Method for making dry powder compositions containing ds-rna based on supercritical fluid technology |
| 02/19/2009 | WO2008127285A3 Target peptides for ovarian cancer immunotherapy |
| 02/19/2009 | WO2006118564A3 MODIFIED CELLS EXPRESSING A PROTEIN THAT MODULATES ACTIVITY OF bHLH PROTEINS, AND USES THEREOF |
| 02/19/2009 | WO2006112869A3 Modulation of cytokine signaling regulators and applications for immunotherapy |
| 02/19/2009 | US20090048435 Oligonucleotide modulation of cell adhesion |
| 02/19/2009 | US20090048201 Use of targeted cross-linked nanoparticles for in vivo gene delivery |
| 02/19/2009 | US20090048191 Therapeutic molecules for modulating stability of vegf |
| 02/19/2009 | US20090048148 Compositions and methods for therapeutic use |
| 02/19/2009 | US20090047735 Antibodies Against Human G-Protein Chemokine Receptor (CCR5) HDGNR10 |
| 02/19/2009 | US20090047733 Avidin-Pseudotyped Viral Vectors and Their Use |
| 02/19/2009 | US20090047668 Novel method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| 02/19/2009 | US20090047339 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| 02/19/2009 | US20090047275 Modulating calvarial osteoblast differentiation; fracture repair |
| 02/19/2009 | US20090047259 Methods of Using the Calcineurin A Variant CnA-beta 1 |
| 02/19/2009 | US20090047217 Polynucleotides Encoding Members of the Human B Lymphocyte Activation Antigen B7 Family and Polypeptides Encoded Thereby |
| 02/19/2009 | CA2733676A1 Microrna compositions and methods for the treatment of myelogenous leukemia |
| 02/19/2009 | CA2695892A1 Non-aggregating virus formulation |
| 02/18/2009 | EP2025757A2 Polymeric immunoglobulin receptor-mediated gene transfer |
| 02/18/2009 | EP2025752A2 Antisense oligonucleotides for the inhibition of expression of type I procollagen |
| 02/18/2009 | EP2025347A1 Prophylactic and therapeutic agent for cancer |
| 02/18/2009 | EP2023961A1 Method for isolating homogeneous populations of transduced progenitors stably expressing specific levels of a transgene |
| 02/18/2009 | EP1636260B1 Improved secretion of neublastin |
| 02/18/2009 | EP1434884B1 Single nucleotide polymorphisms predicting cardiovascular disease |
| 02/18/2009 | EP1135467B1 Psca: prostate stem cell antigen and uses thereof |
| 02/18/2009 | EP1007631B2 Cardiac muscle regeneration using mesenchymal stem cells |
| 02/18/2009 | EP0673415B1 Recombinant viral vector system |
| 02/18/2009 | CN101370513A Immunogenicity polypeptide composed of optimized concealed peptide derived from tumor antigen |
| 02/18/2009 | CN101368187A Recombinant human FUS1 and human IL-12 dual-gene expression carrier, liposome complexes, preparation method and application thereof |
| 02/18/2009 | CN101368173A Antihuman CD44 monoclone antibody hybridoma cell line, monoclone antibody, engineering antibody, carrier, reagent kit and uses thereof |
| 02/18/2009 | CN101367869A Polypeptide for preventing, diagnosing and treating hepatitis E virus, and vaccine as diagnosis agent of the same |
| 02/18/2009 | CN101366950A Uses of gamma-ray combined phTERT-HRP/IAA in medicament for treating cancer of larynx |
| 02/18/2009 | CN101366949A Method for improving feed efficiency and/or growth rate and/or fat reduction of livestock |
| 02/18/2009 | CN100462438C Chimeric type 5/type 11 or type 35 adenovirus vector for preventing infection with antihuman immunodeficiency virus |
| 02/18/2009 | CN100462135C Polyethylenimine derivates nanometer hollow microspheres and the preparing method |
| 02/18/2009 | CN100462104C Targeting-fusion DNA vaccine for caries-prevention, and its prepn. method |
| 02/17/2009 | US7491815 Antisense modulation of C-reactive protein expression |
| 02/17/2009 | US7491550 Diagnostics and therapeutics for diseases associated with Neuromedin U2 receptor (NMU2) |
| 02/17/2009 | US7491538 Gene expression with covalently modified polynucleotides |
| 02/17/2009 | US7491537 Nucleic acid formulations for gene delivery and methods of use |
| 02/17/2009 | US7491525 Specific proliferation in tumour cell which can express antioncogene with high efficiency and the use of it |
| 02/17/2009 | US7491508 termini grow efficiently in desired cell line; left terminus spans the 5' inverted terminal repeat, left terminus spans the E4 region and the 3' inverted terminal repeat; internal regions does not grow efficiently in the desired cell; adenovirus vectors use for gene therapy; culturing; vaccines |
| 02/17/2009 | US7491401 Lawsonia intracellularis vaccine |
| 02/17/2009 | US7491398 Proteins in enteroaggregative Escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections |
| 02/17/2009 | US7491389 Bone marrow; controlling cell differentiation |
| 02/17/2009 | US7491385 Polynucleotide gene expression construction; therapy of diseases caused by damage to excitable tissue; cardiovascular disorders therapy; antidiabetic agents; Parkinson's disease; antiepileptic agents; neurodegenerative agents |
| 02/17/2009 | CA2301874C Suppression of malignancy utilizing ribonucleotide reductase r1 |
| 02/17/2009 | CA2282812C Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
| 02/17/2009 | CA2236455C Human p27kip1 gene promoter |
| 02/17/2009 | CA2233166C Hormone immunomodulated induction of mucosal immune responses |
| 02/12/2009 | WO2009021235A2 Methods and compositions for treating cancer |
| 02/12/2009 | WO2009021232A2 High-throughput, whole-animal screening system |
| 02/12/2009 | WO2009021034A2 Methods of treating b-cell cancers |
| 02/12/2009 | WO2009020645A2 Matriptase protein and uses thereof |
| 02/12/2009 | WO2009020550A2 Composites for biomedical applications |
| 02/12/2009 | WO2009020119A1 Pharmaceutical containing hif-1 alpha and hif-2 alpha expression inhibitor |
| 02/12/2009 | WO2009020028A1 Determination and suppression of expression level of g protein-coupled receptor kinase 4 gene in breast cancer cell |
| 02/12/2009 | WO2009019612A2 Lentiviral gene transfer vectors and their medicinal applications |
| 02/12/2009 | WO2008145400A3 Mutated structural protein of a parvovirus |
| 02/12/2009 | WO2008131807A3 Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
| 02/12/2009 | WO2008131191A8 Nucleic acids hybridizable to micro rna and precursors thereof |
| 02/12/2009 | WO2008102274A3 Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| 02/12/2009 | WO2007096882A3 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| 02/12/2009 | US20090043383 Genetically modified heart valve xenografts |
| 02/12/2009 | US20090043085 Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| 02/12/2009 | US20090043083 Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| 02/12/2009 | US20090043082 Microrna and methods for inhibiting same |
| 02/12/2009 | US20090042830 Novel oncogene, recombinant protein derived therefrom, and uses thereof |
| 02/12/2009 | US20090042828 Nucleic acid with 1st sequence encoding antisense RNAi specific for targeting regions of copper zinc superoxide dismutase that cause inherited amyotrophic lateral sclerosis, and a 2nd sequence encoding a RNAi resistant replacement gene with silent mutations encoding messenger RNA resistant to cleavage |
| 02/12/2009 | US20090042827 Antiviral oligonucleotides targeting hbv |
| 02/12/2009 | US20090042799 Light chain that cleaves a neurosecretory protein; an HN domain that translocates the light chain across an endosome membrane and a substance P targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction |
| 02/12/2009 | US20090042797 Gamma-heregulin |
| 02/12/2009 | US20090042796 Derivatives of the il-2 receptor gamma chain, their production and use |
| 02/12/2009 | US20090042230 Flea allantoinase proteins and uses thereof |
| 02/12/2009 | US20090042199 Nucleotide sequences coding lymphocyte adhesion protein for use in treatment of autoimmunity, inflammation and infection |
| 02/12/2009 | US20090041804 Foreign nucleic acid molecule encoding multiple costimulatory molecules, such as B7-1 or B7-2 (antigens), intercellular adhesion molecules and leukocyte function associated antigen-3 |
| 02/12/2009 | US20090041759 Materials and methods for treating ocular-related disorders |
| 02/12/2009 | US20090041735 CD34 Stem cell-related methods and compositions |
| 02/12/2009 | US20090041731 Treatment for Diabetes |
| 02/12/2009 | US20090041726 Tumor therapy with high affinity laminin receptor-target vectors and combinations with chemotherapeutic agents |
| 02/12/2009 | US20090041718 Methods of Modulating Cytokine Activity; Related Reagents |